Search
Research
Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infantsPapua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.
Research
Safety and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: a randomised controlled trial of PCV in Papua New Guinean infantsInfant vaccination with 3 doses of PCV10 or PCV13 is safe and immunogenic in a highly endemic setting
Research
Predictors of pneumococcal carriage and the effect of the 13-valent pneumococcal conjugate vaccination the Western Australian Aboriginal populationThe PCV7 was introduced to prevent IPD in WA Aboriginal people in 2001 to a lesser extent in older people.
Research
Aboriginal and non-Aboriginal children in Western Australia carry different serotypes of pneumococci with different antimicrobial susceptibility profilesDifferences in pneumococcal serotypes, genotypes, and antimicrobial susceptibility between Aboriginal and non-Aboriginal children living in the same area
Research
Rhinovirus species and clinical features in children hospitalised with pneumonia from MozambiqueThe prevalence of human rhinovirus (RV) species in children hospitalised with pneumonia in Manhiça, Mozambique
Research
Respiratory viruses in young South African children with acute lower respiratory infections and interactions with HIVRV-A and RV-C are endemic in South African children and HIV infection may be protective against RSV and bronchiolitis.
Research
A systematic review of the evidence that swimming pools improve health and wellbeing in remote Aboriginal communities in AustraliaThe benefits that swimming pools may bring to to ear and eye health in remote Aboriginal communities remains unresolved
Research
Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcalThe impact of the 23vPPV booster on IPD incidence among Australian Indigenous children is unclear from regional reports of small case numbers.
The Ear Health team's vision is all children start primary school with good hearing.